For five years until March 2018, Daiichi Sankyo Biotech Co., Ltd. (formerly, Kitasato Daiichi Sankyo Vaccine) cooperated with the Japan International Cooperation Agency (JICA) for the Vietnam POLYVAC* "Measles-Rubella (MR) Vaccine Production Technology Transfer Project." This activity enabled Vietnam to produce a safe and reliable MR vaccine in the country without relying on imports.

In March 2018, the Vietnam-made MR vaccine was incorporated into the Expanded Program on Immunization, and administration of the vaccine to children in Vietnam started. Recently, the MR vaccine has been utilized for epidemics among all people.

We still have a cooperative relationship with POLYVAC and have established a support system to assist POLYVAC in achieving sustainable vaccine production.

Through this activity, we contribute to preventing the infestation of infectious diseases in Vietnam, and thereby contributing to one of the sustainable development goals (SDG) 3 targets of the United Nations. Going forward, we will continue to strive to achieve the SDGs.

* Center for Research and Production of Vaccines and Biologicals in Vietnam